A5106185571- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Sarcoma Diagnosis and Treatment
- Advances in Oncology and Radiotherapy
- Breast Cancer Treatment Studies
- Biosimilars and Bioanalytical Methods
- Peptidase Inhibition and Analysis
- COVID-19 and healthcare impacts
- Breast Lesions and Carcinomas
- Gallbladder and Bile Duct Disorders
- Cancer, Hypoxia, and Metabolism
- Bone Tumor Diagnosis and Treatments
- Cancer Diagnosis and Treatment
- Oral and Maxillofacial Pathology
- Neurofibromatosis and Schwannoma Cases
- Gastrointestinal Tumor Research and Treatment
- Cardiac, Anesthesia and Surgical Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Methemoglobinemia and Tumor Lysis Syndrome
Queen Elizabeth II Health Sciences Centre
2012-2024
Dalhousie University
2000-2024
Cancer Care Nova Scotia
2023-2024
Nova Scotia Health Authority
2023
Nova Scotia Cancer Centre
2002-2022
Health Sciences Centre
2018
Cape Breton Regional Hospital
2010
Duke Medical Center
2002
Response Biomedical (Canada)
2002
University of Chicago
2002
We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil (FAC) as adjuvant chemotherapy for operable node-positive breast cancer.
Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib in combination pembrolizumab improves outcomes compared standard of care (SOC) mismatch repair proficient or not microsatellite instability high (pMMR MSI-H) mCRC.
PURPOSE: The time spent in pursuing treatments for advanced cancer can be substantial. We have previously proposed a pragmatic and patient-centered metric of these costs—which we term toxicity—as any day with physical health care system contact. This includes outpatient visits (eg, bloodwork, scans, etc), emergency department visits, overnight stays facility. Herein, sought to assess toxicity completed randomized controlled trial (RCT). METHODS: conducted secondary analysis the Canadian...
Importance Immune checkpoint inhibitors (ICIs) have limited activity in microsatellite-stable (MSS) or mismatch repair–proficient (pMMR) colorectal cancer. Recent findings suggest the efficacy of ICIs may be modulated by presence liver metastases (LM). Objective To investigate association between LM and ICI advanced MSS Design, Setting, Participants In this secondary analysis Canadian Cancer Trials Group CO26 (CCTG CO.26) randomized clinical trial, patients with treatment-refractory cancer...
Abstract Introduction Although contact days—days with health-care outside home—are increasingly adopted as a measure of time toxicity and treatment burden, they could also serve surrogate treatment-related harm. We sought to assess the association between days patient-reported outcomes prognostic ability days. Methods conducted secondary analysis CO.17 that evaluated cetuximab vs supportive care in patients advanced colorectal cancer. collected European Organisation for Research Treatment...
481 Background: D is a human monoclonal antibody (mAb) that inhibits binding of programmed cell death ligand 1 (PD-L1) to its receptor. T mAb against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Targeting both PD-L1 and CTLA-4 may have additive/synergistic activity as mechanisms action inhibition are non-redundant. This study evaluated whether combining would lead improved pt survival vs BSC alone in rCRC. Methods: Pts with rCRC were randomized 2:1 D+T . eligible if they failed...
PURPOSE: To compare the efficacy and tolerability of eniluracil (EU)/fluorouracil (5-FU) with that 5-FU/leucovorin (LV) as first-line therapy for patients metastatic/advanced colorectal cancer. PATIENTS AND METHODS: This multicenter, randomized, open-label, phase III study (FUMA3008) conducted in United States Canada compared safety EU/5-FU (11.5 mg/m 2 /1.15 twice daily 28 days every 35 days) intravenous 5-FU/LV (425 /20 once 5 previously untreated metastatic Overall survival (OS) was...
The annual Eastern Canadian Colorectal Cancer Consensus Conference was held in Montreal, Quebec, October 22-24, 2009. Health care professionals involved the of patients with colorectal cancer participated presentation and discussion sessions for purposes developing recommendations presented here. This consensus statement addresses current issues management cancer, such as hepatic pulmonary metastases, role monoclonal antibodies to epidermal growth factor receptor, benefits safety...
3512 Background: Targeting both PD-L1 and CTLA-4 may be synergistic immunotherapy approaches. CO.26 evaluated if dual inhibition leads to improved pt survival vs BSC alone in rmCRC. Methods: rmCRC pts were randomized 2:1 D+T BSC. Treatment consisted of D (1500 mg) D1 q 28 days T (75 for first 4 cycles, supportive measures. Primary endpoint was overall (OS). Two-sided p < 0.10 considered statistically significant. Cell-free (cf)DNA sequencing MSI TMB used GuardantOMNI panel baseline...
Trastuzumab beyond first progression in the metastatic setting has been adopted based on limited data suggesting improved outcomes compared to second-line chemotherapy alone although predictive factors for preferential benefit remain elusive. We conducted a retrospective review of all patients receiving trastuzumab HER2 + disease between Jan 1, 1999–June 15, 2011. Univariate and time event analyses described treatment survival patterns. Median duration each line therapy overall times...
TPS240 Background: Emerging evidence suggests neoadjuvant therapy may benefit patients (pts) with advanced colon cancer. Neoadjuvant immunotherapy has shown promising efficacy for early-stage mismatch repair deficient (dMMR) cancer [1,2]. Evidence from other immunogenic tumors that a perioperative approach further improve survival outcomes [3,4]. Dostarlimab (anti-PD-1) favorable benefit:risk profile in previously untreated dMMR locally rectal [5] and dMMR/microsatellite instability-high...
Giant cell tumor of the bone (GCTB) is a rare primary neoplasm, representing about 5% all tumors. Most GCTBs are found in epiphysis long bones, with only 2% involving skull. In recent years, receptor activator nuclear factor Kappa ligand monoclonal antibody denosumab has been demonstrated as promising therapeutic option for GCTB; however, this an evolving field. We present case 57-year-old female GCTB right orbit and sinuses, originally thought to be aneurysmal cyst. Her symptoms included...
Eniluracil (776C85), a potent inactivator of dihydropyrimidine dehydrogenase, allows fluorouracil (5-FU) to be administered orally on schedule that simulates continuous-infusion 5-FU. The primary objective this study was estimate the tumor response rate eniluracil and 5-FU in treatment anthracycline- taxane-resistant advanced breast cancer.Patients with cancer were enrolled onto open-label, phase II, multicenter study. Patients received 1.0 mg/m(2) given 10:1 ratio (eniluracil:5-FU) twice...
The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2017 was held in St. John's, Newfoundland and Labrador, 28-30 September. Experts radiation oncology, medical surgical cancer genetics who are involved the management of patients with gastrointestinal malignancies participated presentations discussion sessions for purpose developing recommendations presented here. This consensus statement addresses multiple topics gastric, rectal, colon cancer, including ■ identification...
The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019 was held in Morell, Prince Edward Island, 19–21 September 2019. Experts medical oncology, radiation and surgical oncology who are involved the management of patients with gastrointestinal malignancies participated presentations discussion sessions for purpose developing recommendations presented here. This consensus statement addresses multiple topics anal, colorectal, biliary tract, gastric cancers, including:...
3587 Background: ICIs have limited efficacy in microsatellite stable (MSS) mCRC. The mechanisms of resistance to ICI remain incompletely understood. Recent findings suggest that erythyroid progenitor cells (EPCs) the tumour microenvironment can exert immunosuppressive properties and promote progression through secretion artemin, a neurotrophic factor. We conducted this post-hoc analysis Phase II CCTG CO.26 trial (NCT02870920) investigate relationship between artemin treatment outcomes MSS...
183 Background: In response to energetic stress, colorectal cancer cells secrete creatine kinase brain-type (CKB). CKB converts and ATP from the extracellular matrix PC, which is imported intracellularly sustain survival metastatic spread. addition, PC modulates immune cell functions may play a role in mediating responses checkpoint inhibition. CO.26 was phase II trial (NCT02870920) that randomized patients (pts) with refractory mCRC durvalumab plus tremelimumab (D+T) versus best supportive...
BackgroundABP 215 is a biosimilar to the reference product, bevacizumab, and was one of first biosimilars approved by Health Canada for first-line treatment metastatic colorectal cancer (mCRC). This study aimed address gaps in real-world evidence (RWE) including patient characteristics, safety (primary objective), effectiveness (secondary objective) ABP therapy Canadian patients with mCRC.Materials MethodsRetrospective data were collected 2 waves, at least 1 year (Wave 1) or years 2) after...
Tumor Lysis syndrome (TLS) is a well-known oncological emergency. It most commonly associated with bulky and highly proliferative tumors such as leukemias lymphomas where destruction of cells, usually from chemotherapy, leads to hyperuricemia, hyperkalemia, hyperphosphatemia hypocalcemia. Such metabolic derangements can lead renal failure potentially fatal cardiac arrhythmias. New biologically directed therapies imatinib mesylate, selective tyrosine kinase inhibitor against the...
Abstract Background: The first case of COVID-19 (SARS-CoV-2, C19) was reported to Health Canada on Jan 25th, 2020. By March 18th, states emergency were declared across multiple provinces. pandemic has presented professional and personal challenges for the medical oncology workforce cancer care. Under auspices Canadian Association Medical Oncology (CAMO), we sought examine temporal effects C19 oncologists care practices Canada. Methods: Two serial multiple-choice, web-based national surveys...
3600 Background: Immune checkpoint blockade has limited activity in microsatellite-stable (MSS) or mis-match repair proficient (pMMR) CRC. Recent findings suggest that immunotherapy efficacy may be modulated by the presence of liver metastases. We conducted a retrospective analysis Canadian Cancer Trials Group (CCTG) CO.26 study to investigate relationship between metastases and immune blockade. Methods: The CCTG was randomized phase II (NCT02870920). Pts with treatment refractory CRC were...